12 Stocks Under $10 With High Upside Potential

Page 9 of 11

3. ImmunityBio, Inc. (NASDAQ:IBRX)

Share Price: $3.02

No. of Hedge Fund Holders: 15

Analyst Upside Potential: 131.79%

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company developing therapies and vaccines that support the natural immune system to defeat cancers and infectious diseases. The biotech firm is making massive strides and has had a remarkable start to 2025.

ImmunityBio, Inc. (NASDAQ:IBRX) recently obtained the Food and Drug Administration’s (FDA) Regenerative Medicine Advanced Therapy designation for ANKTIVA and CARNK to treat lymphopenia and pancreatic cancer. Earlier in February, the FDA authorized ImmunityBio to help address the supply shortage of bladder cancer treatments in the U.S. by bringing a vital alternative source of BCG (Bacillus Calmette-Guérin).

Moreover, the issuance of the permanent J-code in January 2025 has helped the company to increase sales momentum. The company’s February 2025 unit sales volume soared 67% over January and January’s unit sales combined exceeded unit sales achieved for all of Q4 2024. In Q4 2024, the company reported a net product revenue of $7.2 million, up by 21% from the previous quarter.

Page 9 of 11